CPC C07K 14/5434 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464412 (2023.05); A61K 39/46444 (2023.05); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 16/2803 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/20 (2013.01); C07K 2319/33 (2013.01)] | 18 Claims |
1. A modified cell comprising an effector module, wherein said effector module comprises:
(a) a payload of interest, said payload comprising a membrane-associated Interleukin 12 (IL12),
wherein the membrane-associated IL12 is a fusion protein comprising IL12 subunit beta (p40), IL 12 subunit alpha (p35), at least one linker, and a transmembrane domain; and
(b) a stimulus response element (SRE) comprising a region of Human phosphodiesterase 5 (hPDE5) corresponding to amino acids 535-860 of SEQ ID NO:1, wherein the region further comprises mutation R732L, and wherein the SRE is responsive to or interacts with at least one stimulus.
|